Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026
Zentek Rg (Canada Venture Exchange)
Závěr k 13.2.2026 Změna (%) Změna (CAD) Objem obchodů (CAD)
0,86 -4,44 -0,04 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2026
Popis společnosti
Obecné informace
Název společnostiZentek Ltd
TickerZEN
Kmenové akcie:Ordinary Shares
RICZEN.V
ISIN-
Poslední známé roční výsledky31.03.2025
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 31.03.2025 17
Akcie v oběhu k 03.02.2026 107 523 555
MěnaCAD
Kontaktní informace
Ulice24 Corporate Ct
MěstoGUELPH
PSČN1G 5G5
ZeměCanada
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 056 180 900
Fax17056180900

Business Summary: Zentek Ltd. is an intellectual property technology company. The Company is focused primarily on commercializing ZenGUARD, as well as on the development of certain aptamer technologies and other nanomaterials-based technologies. ZenGUARD is the Company’s patented anti-microbial coating technology platform. Its platform, ZenGUARD, has been shown to have enhanced bacterial and viral filtration efficiency for surgical masks and heating, ventilation, and air conditioning (HVAC) systems. The Company is also focused on the research, development and commercialization of novel products, seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. The Company has installed industrial-scale production equipment to produce the ZenGUARD coating formulation. The Company is also working on developing processes to synthesize graphene, GO and graphene quantum dots, along with other possible applications for graphene-based materials.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Zentek Ltd revenues increased from C$21K to C$64K. Net loss decreased 33% to C$3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share-based compensation decrease of 81% to C$191K (expense), Other income (expense) increase from C$520K (expense) to C$1K (income).
Odvětvová klasifikace
TRBC2009Mining / Metals - Specialty
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Mining & Metals - Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 14.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorMohammed Jiwan-01.12.202501.12.2025
Chief Financial OfficerWendy Ford-01.12.202516.05.2022
Senior Vice President - Strategy and Business DevelopmentRyan Shacklock-
Chief Science OfficerColin Van Der Kuur-04.02.2020
Vice President - Development (AGC)Peter Wood-01.01.2013